Ratings by Noble Capital (Gregory Aurand)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/3/2023 | Baudax Bio Inc. | BXRX | Downgrade | Market Perform (Outperform) |
3.18 (0.19) |
-94.03% | Details | |
| 12/1/2022 | Baudax Bio Inc. | BXRX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/31/2022 | Baudax Bio Inc. | BXRX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/11/2022 | Ortho Regenerative Technologies Inc. | ORTIF | New Coverage | Outperform (N/A) |
0.21 (0.20) |
-4.76% | Details | |
| 3/17/2022 | Baudax Bio Inc. | BXRX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2022 | Baudax Bio Inc. | BXRX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2022 | Baudax Bio Inc. | BXRX | New Coverage | Outperform (N/A) |
0.23 (0.19) |
-17.39% | Details |
